Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Virtual Reality-Supported Autism Education for Nursing Students (VR-AUTISM-NURS)

12 novembre 2026 mis à jour par: Edanur Tar Bolacali, Kirsehir Ahi Evran Universitesi

Effect of a Virtual Reality-Supported Autism Education Program for Nursing Students on Autism-Related Knowledge, Awareness, and Attitudes: A Randomized Controlled Trial

The goal of this clinical trial is to learn if a virtual reality (VR)-supported autism education program improves knowledge, awareness, and attitudes about autism spectrum disorder (ASD) in fourth-year nursing students. The main questions it aims to answer are:

  • Does the program increase nursing students' knowledge of autism?
  • Does the program increase their awareness of autism and improve their attitudes toward people with autism?

Researchers will compare students who take the program with students who receive no education during the study, to see if the program improves knowledge, awareness, and attitudes, and whether these effects last one month after the program.

Participants will:

  • Attend one 90-minute face-to-face session per week for 8 weeks (education group only). Sessions in weeks 1 to 7 use active learning methods such as group work and brainstorming. In week 8, each student watches a short (about 5-minute) 360-degree VR scenario that shows a hospital visit from the point of view of a child with autism, followed by a guided group discussion.
  • Complete questionnaires on autism knowledge, awareness, and attitudes before the program, after the program (week 8), and one month later.

Students in the control group will be offered the same program after the study ends.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

Background: Nurses working in primary care and child health services are in a key position to recognize early signs of autism spectrum disorder (ASD) and to refer children for timely assessment. However, nursing students often report limited knowledge and low confidence in this area. Immersive virtual reality (VR) allows learners to experience sensory and social situations from the perspective of a child with autism without involving children in the teaching process.

Design: This is a single-center, two-arm, parallel-group, open-label randomized controlled trial with pretest, posttest, and one-month follow-up measurements. The study will be reported according to CONSORT and the CONSORT-Outcomes 2025 extension.

Randomization: After baseline measurement, participants will be allocated 1:1 by simple randomization using a computer-generated sequence (randomizer.org). Randomization will be performed by an independent researcher not involved in delivering the intervention, and the allocation list will be concealed from the research team until assignment is complete. Data will be coded by group (Group A/Group B) and analyzed by a statistician blinded to group allocation.

Intervention content: Weekly modules cover the diagnostic framework of ASD, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes. Teaching methods include station rotation, six thinking hats, brainstorming, the six-shoe technique, and cooperative learning (inner-outer circle). Week 8 is a simulation session ("A Journey into the World of a Child with Autism") in which students experience an 8-year-old child's hospital visit first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing. Content will be reviewed by autism experts and piloted with nursing students before the trial.

Statistical analysis: Group-by-time effects across the three measurements will be analyzed with two-way repeated-measures ANOVA, or the nonparametric F1-LD-F1 model if assumptions are not met. Analyses will follow the intention-to-treat principle, and missing data will be handled by multiple imputation. Effect sizes (Cohen's d, partial eta squared) will be reported. The significance level is p<0.05.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Fourth-year student in the Department of Nursing, Faculty of Health Sciences, Kirsehir Ahi Evran University
  • Has completed the pediatric (child health and diseases) nursing course
  • Has not previously attended a structured education program on autism spectrum disorder
  • Agrees to participate voluntarily and signs the informed consent form
  • Is able to attend the education sessions and measurements

Exclusion Criteria:

  • Known health condition that may prevent the use of virtual reality (e.g., severe motion sickness or vertigo, epilepsy)
  • Not completing the baseline (pretest) measurements

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: VR-Supported Autism Education

Participants will attend an 8-week modular autism education program with one 90-minute face-to-face session per week. Weeks 1-7 consist of active learning modules on autism spectrum disorder. Week 8 consists of a virtual reality simulation session followed by a structured debriefing.

An 8-week program with one 90-minute face-to-face session per week. Weeks 1-7 cover the diagnostic framework of autism spectrum disorder, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes, using station rotation, six thinking hats, brainstorming, six-shoe technique, and cooperative learning methods. In week 8, each student experiences an approximately 5-minute immersive 360-degree VR scenario of an 8-year-old child's hospital visit from the child's perspective, first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing.

Aucune intervention: Control

Participants will receive no education during the study period and will complete the same questionnaires at the same time points (baseline, week 8, and week 12). They will be offered the same education program after the follow-up measurement.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Autism Knowledge Score (Knowledge about Childhood Autism among Health Workers Questionnaire)
Délai: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism knowledge will be measured with the Turkish version of the Knowledge about Childhood Autism among Health Workers (KCAHW) Questionnaire. It has 19 items covering social interaction, communication, behavioral patterns, and features of the disorder. Each correct answer scores 1 and each incorrect or "don't know" answer scores 0, giving a total score of 0 to 19. Higher scores indicate greater knowledge of childhood autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Autism Awareness Score (Autism Awareness Scale)
Délai: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism awareness will be measured with the Autism Awareness Scale, which has 32 items in 7 subscales (restricted interests and repetitive behaviors, social interaction and communication, causes of autism, peer relationships, key elements of intervention, physical characteristics, and early warning signs). Items are rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), with reverse-scored items, giving a total score of 32 to 160. Higher scores indicate greater awareness of autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)
Attitudes Toward Autism Score (Societal Attitudes Towards Autism Scale)
Délai: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Attitudes toward autism will be measured with the Turkish version of the Societal Attitudes Towards Autism (SATA) Scale, which has 26 items in 3 subscales (personal distance, knowledge, and social life). Items are rated on a 4-point scale, with reverse-scored items, giving a total score of 26 to 104. Higher scores indicate more positive attitudes toward individuals with autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

17 novembre 2026

Achèvement primaire (Estimé)

15 janvier 2027

Achèvement de l'étude (Estimé)

28 février 2027

Dates d'inscription aux études

Première soumission

12 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • SYO.A3.26.005

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared publicly because participants were informed in the consent process that their data would be used only by the research team for scientific purposes. Aggregate results will be published in a peer-reviewed journal. De-identified data may be made available by the principal investigator upon reasonable request after publication, subject to ethics committee approval.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .